May 17, 2016 | Infographic, Research Partnership
Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.
Did you know that last year Research Partnership conducted over 250 projects in over 55 countries, including 35 emerging markets?Â
Download the infographic:Â http://www.researchpartnership.com/news/2016/03/infographic-corporate/?utm_source=Research%20Partner…
This content was provided by Inizio
Latest Content from Inizio
Research Partnership’s client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks; the main burden of disease is not just…
Living with Ankylosing Spondylitis (AS) & nr-AxSpA are reports based on quantitative studies conducted online in the 5EU and US. The AS 5EU report comprises of interviews with 385 patients…
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST
We’re sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland.
We are delighted to announce that an entry by Janssen and Research Partnership for the 2019 EphMRA MR Excellence Awards has been awarded runner-up in the ‘Business Impact through Innovation’…
Asia is home to 60% of the world’s population and is one of the fastest growing vaccine markets in the world. A rising demand for better healthcare infrastructure and high…
Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam in March.This two-day event was attended by over 600 delegates, including a number…
Visit us on stand number 311
Research Analyst Rachel Arthurs explores how public exposure to the complications of food allergy has affected attitudes toward treatment.In recent years, there has been a noticeable shift in the increased…
The best performing privately-owned UK pharmaceutical businesses were revealed earlier this month with the publication of Pharma Times’ Alantra Pharma Fast 50 annual report.Read more about this report here
